PDCD1 and non-small cell lung carcinoma: With the recent rapid development in immunotherapy, immune checkpoint drugs—especially inhibitors of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1)—have made breakthroughs in the treatment of NSCLC, particularly in cases without targetable driver mutations.